Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults (BOOST-X)
2026年8月5日 更新者:Florida Institute for Human and Machine Cognition
Aging-related functional declines are thought to be caused by hallmark biological processes that ultimately manifest in physical, mental, and metabolic impairments to compromise intrinsic capacity and healthspan.
Exercise is the only multipotent treatment with promise to mitigate many of the aging hallmarks, but there is substantial variability in individual exercise responsiveness.
Thus, the investigators approach to boosting exercise responsiveness in aging is to combine an exercise training prescription containing both endurance and resistance training (in alignment with DHHS guidelines) with a nitrate-enriched dietary supplement to augment the cellular, tissue, and systemic adaptations that induce myriad health benefits of exercise in older adults.
調査の概要
状態
まだ募集していません
詳細な説明
Aging-related declines in health and intrinsic capacity are linked to biological processes profoundly affecting all organ systems and tissues including skeletal muscle.
Exercise is a multipotent countermeasure to these processes.
However, there is significant inter-individual response heterogeneity (IRH) in the magnitude of exercise-induced health benefits.
Boosting exercise responsiveness among older adults is thus a top priority.
The investigators have found in older adults that supplementation with nitric oxide (NO) precursors nitrate and nitrite is safe, well tolerated, and improves: (i) physical performance; (ii) vascular endothelial function; (iii) mitochondrial function; (iv) oxidative stress; and (v) muscle inflammation.
The investigators suspect deficits among some older adults in nitrate bioavailability and/or exercise-induced NO production may in part drive suboptimal exercise responsiveness.
Given the powerful and sustaining impact of exercise-induced health benefits on morbidity and mortality, the investigator's fundamental premise is that exercise responsiveness of every older adult should be maximized.
In the BOOST-X Trial the investigators will determine if increasing nitrate bioavailability via dietary supplementation is an efficacious approach to more older adults attaining these essential health benefits.
Low cardiorespiratory fitness (CRF, VO2max) and low functional muscle quality (fMQ; strength/muscle mass) are multi-system manifestations of degenerative aging that include vascular endothelial and mitochondrial dysfunction, oxidative stress, and inflammation.
CRF and fMQ are modifiable with endurance (ET) and resistance (RT) training.
This planned trial will be the first to evaluate the efficacy of coupling a nitrate-rich nutritional supplement with a combined ET+RT prescription in line with DHHS weekly exercise guidelines.
The investigators will test the central hypothesis that daily nitrate supplementation will augment exercise training-induced gains in CRF and fMQ accompanied by improvements in vascular endothelial and mitochondrial function.
Aim 1: Assess the clinical impact of nitrate supplementation on the proportion of older adults attaining exercise-induced health benefits.
N=226 participants stratified by sex and age group (60-69 vs ≥70 y) with random assignment to nitrate (400 mg, 2x/day) (n=113) vs. placebo (nitratedepleted) (n=113) during 12 wk of 3x/wk ET+RT.
1˚ Outcomes: MCID attainment for CRF and fMQ.
Expected Results: Daily nitrate will reduce the proportion of older adults not attaining CRF and fMQ MCIDs by a full 1/3.
Aim 2: Assess potential mechanisms underpinning adaptations to exercise +/- nitrate supplementation.
The investigators will test/integrate in vivo, ex vivo, in vitro and molecular mapping assays considered central to exercise +/- nitrate adaptations and leverage a multidimensional learning framework to better understand the biocircuitry underpinning MCID attainment.
1˚ Outcomes: Vascular endothelial function, muscle mitochondrial function.
Expected Results: MCID attainment will be closely linked to improvements in vascular endothelial function and muscle mitochondrial function.
The acute molecular responses to exercise will be differentially regulated by nitrate supplementation, and the novel biocircuitry will reveal key features that influence adaptability.
研究の種類
介入
入学 (推定)
226
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Craig Tuggle, MA
- 電話番号:850-202-4416
- メール:ctuggle@ihmc.org
研究場所
-
-
Florida
-
Pensacola、Florida、アメリカ、32502
- Florida Institute for Human and Machine Cognition
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
はい
説明
Inclusion Criteria:
- Male or female aged 60 years or older
- Free of chronic disease or disorder that would preclude full participation or have the potential to confound results
- No structured exercise program (2 or more bouts/wk) within previous 12 months
- Cognitively capable of providing informed consent
Exclusion Criteria:
- BMI ≥ 30.0 kg/m2
- Neurodegenerative disease
- Neuromuscular, musculoskeletal or orthopedic disorder or condition that would limit ability to perform the exercise prescription and/or physical performance testing
- Diagnosed orthostatic hypotension, i.e., a drop in systolic blood pressure of at least 20 mmHg or a drop in diastolic blood pressure of at least 10 mmHg within three minutes of standing up from a sitting or lying position.
- Resting blood pressure <90/60 mmHg or >160/95 mmHg
- Uncontrolled hypertension
- Any current cardiovascular disease or cardiopulmonary instability
Recent cardiovascular event or procedure within the preceding 6 months
- If valve replacement has been performed, patient may not be enrolled for 12 months after the procedure
- Any mechanical valve replacement that requires continuous warfarin anti-coagulation
- Anemia: Hgb <11.0 (♂),10.0 (♂) gm/dl
- Diabetes with HgbA1c >7.0% or fasting blood glucose ≥ 130 mg/dl
- Liver disease with ALT > 52 U/l)
- Chronic kidney disease (eGFR < 45)
- Any current infectious disease
- Any other disease or disorder that could influence exercise response, preclude full participation or have the potential to confound results (e.g., chronic lung disease, cognitive impairment, current cancer diagnosis or within 2 yr remission, cerebrovascular disease, pain)
- Life expectancy < 1 year Medications / lifestyle
- Insulin sensitizing/blood glucose lowering agents such as metformin
- Currently on or have used GLP-1 agonist or other metabolic / weight loss drug in previous 12 weeks
- Use of nitrate medications
- High dose statin (≥40 mg/d simvastatin equivalence)
- Chronic corticosteroids
- Testosterone or other anabolic/androgenic hormone therapy
- Lidocaine allergy
- Regular tobacco use and/or vaping > 1/wk
- Use of cannabis > 1/wk
- Excessive alcohol consumption (3 drinks/d or 7 drinks/wk for females; 4 drinks/d or 14 drinks/wk for males)
- Use of illicit drugs (e.g., cocaine, opioids)
- Unable to commit to ~4 months required to complete the study
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Nitrate Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-enriched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
|
|
プラセボコンパレーター:Placebo Group
Participants will be randomized to an intervention in which they take 800 mg (2 x 400 mg) nitrate-deprived, manufacturer-matched beetroot juice drink [Beet It Sport Nitrate 400 (70 ml per drink)].
Both nitrate and placebo will be purchased from Beet It.
|
All participants: An exercise dose will be composed of 12 wk of 3d/wk laboratory based supervised prescribed with strategic variations in intensity, volume, and modality across the 3 weekly sessions.
During Monday and Friday RT sessions, participants complete 3 sets x 8-12 reps to volitional fatigue for leg press, knee extension, leg curl, overhead press, lat pulldown or row, and chest press in superset fashion with a 60 s rest between supersets.
On Wednesday, participants perform 2 sets of 13-15 reps of leg press, knee extension, chest press and lat pulldowns with specific cues for speed and fast contractions.
RT is complemented by the ET component which follows a Moderate-High Moderate intensity schedule with 30 min of 70-75% HRR steady state cycling on Monday and Friday separated by a Wednesday 20 min high intensity interval session on a cycle ergometer (1 min on/off; 10 cycles) at near maximal intensity with a target of 90% HRR.
Manufacturer-matched placebo that is nitrate-depleted beetroot juice (70 ml per drink).
Both nitrate and placebo will be purchased from Beet It.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assess the clinical impact of nitrate supplementation on a proportion of older adults attaining exercise-induced health benefits.
時間枠:12 weeks
|
The primary outcome will be assessed using logistic regression with the proportion not attaining Cardiorespiratory Fitness and functional Muscle Quality Minimally Clinical Differences as the response variable and treatment adjusted for sex and age group across the 12 week intervention.
|
12 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cardiorespiratory demand during submaximal cycle exercise.
時間枠:12 weeks
|
Supportive analyses will include secondary (cardiorespiratory demand during submaximal steady state exercise) outcomes.
The steady state exercise cycling will be 10 minutes at 60% of peak power (Watts) during the VO2 peak test.
|
12 weeks
|
|
Neuromuscular fatiguability during isometric holds.
時間枠:12 weeks
|
The knee extensors will perform a 30 second isometric flexion on a dynamometer.
The fatigue will be defined by the force decline across the 30 seconds.
|
12 weeks
|
|
10 meter max gait speed.
時間枠:12 weeks
|
Participants will walk as quickly as possible across a 10 meter, straight course.
Time is recorded for up to three attempts.
A lower time indicates a faster speed.
|
12 weeks
|
|
modified Balance Error Scoring System (mBESS)
時間枠:12 weeks
|
Stability is assessed with the Sway Medical tablet app via three stances: double-leg, single-leg, and tandem.
Scoring is decided by losing balance or opening eyes during closed eyed tests.
|
12 weeks
|
|
NIH PROMIS Physical Function SF
時間枠:12 weeks
|
The NIH PROMIS Physical Function Short Form (SF) is a standardized tool used to evaluate an individual's physical abilities and limitations in daily activities.
It is part of the broader Patient-Reported Outcomes Measurement Information System (PROMIS), which focuses on measuring patient-reported outcomes across various health domains.
|
12 weeks
|
|
NIH PROMIS Fatigue SF
時間枠:12 weeks
|
PROMIS Fatigue SF refers to the short form of the Patient-Reported Outcomes Measurement Information System designed to assess fatigue levels in patients.
It provides a standardized way to measure fatigue, which can be used in various clinical settings to evaluate patient health status.
|
12 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cognitive function.
時間枠:12 weeks
|
Cognitive function is assessed via Sway Medical reaction time via three assessments: visual processing speed: measures how quickly a person can interpret visual information.
|
12 weeks
|
|
Psychological state.
時間枠:12 weeks
|
Depression and anxiety are assessed via the well-validated Patient Health Questionnaire 9 (PHQ-9) both via Sway.
The PHQ-9, or Patient Health Questionnaire-9, is a tool used to screen for, diagnose, and measure the severity of depression.
It consists of nine questions that assess how often a person has experienced symptoms of depression over the past two weeks.
|
12 weeks
|
|
Sleep quality and nocturnal stress.
時間枠:12 weeks
|
Perceptions of sleep quality are measured using the short forms (SF) of PROMIS Sleep Disturbance and Sleep-Related Impairment.
For direct monitoring, participants wear an Oura Gen-4 ring to quantify sleep behavior with stress monitored via Heart Rate /Heart Rate variability (HRV) across the full enrollment period, as we have done in previous studies including the ongoing NIA M3AX Trial (NCT06507189).
The Oura ring is well validated against polysomnography for several sleep metrics and nocturnal HR/HRV.
|
12 weeks
|
|
Free-living activity via the Oura Gen 4.
時間枠:12 weeks
|
Free-living activity is also monitored daily via the Oura Gen-4 ring worn throughout trial participation.
Variables such as step count and heart rate will used to determine activity.
|
12 weeks
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年11月1日
一次修了 (推定)
2031年5月1日
研究の完了 (推定)
2031年5月1日
試験登録日
最初に提出
2026年4月17日
QC基準を満たした最初の提出物
2026年4月30日
最初の投稿 (実際)
2026年5月7日
学習記録の更新
投稿された最後の更新 (実際)
2026年8月10日
QC基準を満たした最後の更新が送信されました
2026年8月5日
最終確認日
2026年4月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- IRB-2026-0019
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
De-identified phenotyping data will be made accessible through supplementary data tables and files alongside manuscript publication or via third-party repositories.
This data will also be hosted on secure server space without any link to PHI and made accessible through a publicly available Shiny app.
Primary cell aliquots and biobanked snap frozen muscle and/or frozen blood samples will be provided to investigators upon reasonable request along with de-identified metadata.
IPD 共有時間枠
Data share will begin when as soon as first data collections begin.
Sub award sites will enter participant data on the secure Data Entry Management System (DEMS).
Data shares will continue until the close of study.
IPD 共有アクセス基準
Access to all study data is granted on the researcher regulatory training and local IRB approval.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。